Immune responsiveness to squaric acid dibutylester in human subjects.
Authors
Baron ED; Swick AR; Ryan CA; Gerberick GF; Tinkle SS; Nedorost ST; Cooper KD; Stevens SR
Source
Working Partnerships: Applying Research to Practice, NORA Symposium 2003, June 23-24, 2003, Arlington, Virginia. Washington, DC: National Institute for Occupational Safety and Health, 2003 Jun; :26
Link
NIOSHTIC No.
20023334
Abstract
Understanding dose-response characteristics is essential in the prevention of allergic contact dermatitis. Squaric acid dibutyl ester (SADBE) is a known contact sensitizer, but dose-response data have not been reported. This study is aimed at determining the relationship between sensitization dose and contact hypersensitivity (CHS) response to SADBE in human volunteers and investigating the correlation of clinical response with T-cell proliferation in vitro. Thirty-six healthy volunteers were sensitized to either .025,.05,.1 or .5% SADBE on the buttock, followed two weeks later by elicitation on the arm using 5 graded doses from 0 to 1%. An additional control group of 10 subjects underwent elicitation without prior sensitization. 180 cc of blood was obtained immediately prior to sensitization and elicitation. In some subjects, blood was also obtained 4-10 months after elicitation. Results show that there is a direct relationship between sensitization dose and immune response. The SADBE dose capable of sensitizing 50% of the population was .05%. Although the T-cell proliferation assay was not sensitive enough to detect changes two weeks after sensitization, but prior to elicitation, post-elicitation analyses revealed that sufficient numbers of circulating reactive T cells are present to allow detection by in vitro methods. These results suggest that either time (4-10 months) or re-exposure is necessary for this expansion of reactive T-cell numbers.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.